E-cadherinP120^(ctn)在乳腺癌中的表达及意义  

Expression and significance of E-cadherin and P120 catenin in breast cancer

作　　者：金夏祥[1] 诸炯[1] 王爱忠[1] 俞国冰[1] 邬丹钰[1] 唐晓兰[1] 

机构地区：[1]宁波解放军第113医院病理科,浙江省宁波市315040

出　　处：《中国肿瘤临床》2013年第3期144-147,共4页Chinese Journal of Clinical Oncology

摘　　要：目的:探讨E-钙黏蛋白(E-cadherin,E-cad)、P120连环蛋白(P120ctn)在乳腺浸润性导管癌(IDC)和浸润性小叶癌(ILC)中的表达及其鉴别诊断意义。方法:收集解放军第113医院2007年12月至2012年5月间有完整随访资料的浸润性导管癌60例、浸润性小叶癌48例及混合性癌20例。采用免疫组织化学S-P法检测E-cad及P120的表达。结果:E-cad在IDC和ILC中的阳性率分别为85%(51/60)和0,其差异有统计学意义(P<0.01);P120在IDC中阳性率为100%,且均为细胞膜着色,而在ILC中阳性率亦为100%,但均为胞浆着色。E-cad和P120联合使用将20例混合癌确诊为IDC 16例及ILC 4例。IDC中E-cad的表达水平与肿瘤分期无关,与淋巴结转移有关(P<0.05)。结论:E-cad和P120联合使用可以鉴别光镜下易混淆的IDC和ILC,使组织分型更准确,建议应用于乳腺癌的常规免疫组织化学检测。E-cad的表达水平与淋巴结转移有关。Objective：To explore the expression of E-cadherin and p 120 catenin in invasive ductal carcinoma （IDC） and invasive lobular carcinoma （ILC） and their significance for differential diagnosis. Methods：A total of 60cases with IDCs, 48invasive lobular carcinomas, and 20 invasive carcinomas with mixed ductal and lobular features were collected from No. 113 Hospital of People＇s Liberation Army. An immunohistochemical study for E-cadherin and P 120 catenin was performed using a streptavidin –peroxidase method. Results： The positivity rates for E-cadherin in IDC and classic ILC were85 % （51 /60 ） and0%, respectively （P〈0.01 ）. The positivity rates for p 120 catenin were100% in both IDC （membranous staining） and classic ILC （cytoplasmic staining）. E-cadherin and p120 catenin were used to classify20mixed carcinomas into16IDCs and 4 ILCs. No significant difference was found in E-cadherin expression level in different histological types of IDC was indicated. However, E-cadherin expression was coincided with lymph node metastasis （P〈0.05 ）. Conclusion： E-cadherin and p120 catenin are useful immunomarkers to distinguish IDCs from ILCs and thus can be used in routine immunohistochemistry in breast cancer. The E-cad expression level coincides with lymph node metastasis in IDC.

关 键 词：乳腺癌钙黏着糖蛋白类 连环素类 免疫组织化学 鉴别诊断 

分 类 号：R737.9[医药卫生—肿瘤]